Jan Bell Email & Phone Number

Thousand Oaks, Ca, Us

• Promote IV immunotherapy oncologic BITE technology antibody construct Blincyto (Acute Lymphoblastic Leukemia).• Call on Adult/Pediatric Hematologists and BMT Specialists in major academic centers, regional hospitals and Dept. of Defense institutions and develop productive KOL relationships.• Partner with stakeholders in the malignant rare disease space across the MD, NJ, DE, DC, and VA region.• Employ a relationship based and consultative sales approach to understand provider approach and clinical needs.• Implement effective marketing strategies to successfully position product in disease landscape.• Key Accomplishments:- Gained product adoption at Johns Hopkins, UMMC, UVA, MedStar/GU/, Hackensack/JSUMC, INOVA, Walter Reed, UVA Health, Virginia Cancer Specialists, Children’s National Hospital, Christiana Hospital, Cooper U./MD Anderson.- Recognized for successes with Team Excellence Awards in 2020, 2021. - Developed and led Account Mapping/Stakeholder Analysis training workshops 2020-2022.- Nominated by Leadership for L.E.A.D. initiative, national leadership program 2021-2022.- Selected to serve as Sales Operations Lead role in 2021-2022 and Culture Lead role 2020-2021.- Driving for Results Award Recipient/National Leukemia Team in 2020.

Thousand Oaks, Ca, Us

Neulasta/Onpro device (leukocyte growth factor), Vectibix (EGFR - metastatic colorectal cancer) Imlygic (genetically modified oncolytic viral therapy -melanoma), Xgeva (bone mets), Nplate (immune thrombocytopenia).• Called on Oncologists/Hematologists across the Washington DC, Maryland, and Virginia region.• Employed a relationship-based and consultative sales approach in hospitals and cancer centers.• Created opportunities within the territory proactively to maintain and grow product market share.• Planned and executed the territory businesses plans to focus on the pull-through of brand messaging.• Identified and fostered relationships with Key Opinion Leaders and planned and executed speaker programs.• Key Accomplishments:- Won the Mid-Atlantic Region Wave Award based on SGA and outstanding leadership in S1 2017.- Launched and operationalized Imlygic, the first genetically engineered intra-lesional oncolytic for melanoma. - Spearheaded hospital multi-step process to achieve formulary approvals for Neulasta injection device. - Selected to represent the District as the Xgeva Product Lead and rolled out new product initiatives.- Won the OBU Contests during Neulasta device launch.

Boston, Ma, Us

• Represented Merck Oncology portfolio. Managed sales and marketing for an oncology portfolio including Intron A, Sylatron, Temodar, Emend.• Called on Oncologists in academic centers and cancer centers across the Chicago region.• Initiated and facilitated medical education program on Treatment Strategies for CINV at Rush University.• Partnered with Northwestern Memorial Melanoma KOLs and pharmacy managers to gain formulary approval. • Utilized a combination of market analysis, strategic planning, and advanced selling skills to drive sales growth.• Key Accomplishments:- Influenced key decision makers to positively impact the Rush System EMR anti-emetogenic protocols.- Achieved formulary win for Sylatron and gained melanoma protocol inclusion at Northwestern Memorial.- Increased protocol adherence for CINV and achieved program utilization for Joint Commission credentialing.- Collaborated to develop a Think Tank forum with Lurie Cancer Center/Northwestern focused on Integrating Quality Initiatives into the Oncology Practice program with large stakeholder participation.

Foster City, Ca, Us

• Promoted Ranexa (anti-ischemic/anti-anginal therapy) across four states in the Midwest region.• Called on Cardiologists in hospitals and Cardiology Clinics. • Focused on building trusted and respected relationships with providers and office staff through consultative selling.• Key Accomplishment: Increased product access with reimbursement resources.

Indianapolis, Indiana, Us

• Marketed a portfolio of IV products including Reopro (monoclonal antibody initiated in cardiac cath lab), Xigris (biologic-Severe Sepsis/Septic Shock), Humulin (insulin), and Effient (P2Y12 platelet inhibitor) in hospitals in Chicago.• Called on Interventional Cardiology, Pulm/Critical Care, Hem/Onc, Infectious Disease, Trauma, and Emergency dept.• Key Accomplishments:- Ranked in the Top 10% nationally for Reopro Market Share growth with 122% in 2010 and159% in 2011- Achieved major product conversion at Northwestern Memorial Hospital for Humulin.- Recognized with District Achievement Award in 2004 and won quota trips in 2004, 2009, and 2010.

Master Of Business Administration - Mba, Health/Health Care Administration/Management

Bachelor Of Arts - Ba, Business Administration And Management, General

Fashion Merchandising/Marketing Management